Sublingual esketamine for PTSD. The same inflammatory pathways that drive PTSD also appear in autoimmune disease — an exploratory neuroimmune signal we are measuring in the pilot.
*Sertraline (1999) and paroxetine (2001) are the only FDA-approved PTSD medications. Both are 1990s SSRIs. No novel mechanism has been approved in over 25 years. Sources: FDA, SAMHSA, Grand View Research.
Emerging evidence shows that PTSD is associated with chronically elevated levels of pro-inflammatory cytokines — including IL-6, IL-1β, TNF-α, and CRP — that persist long after the traumatic event. These biomarkers disrupt hippocampal neurogenesis, impair BDNF signaling, and perpetuate the hyperarousal and avoidance symptoms that define the disorder.
Existing pharmacotherapies — SSRIs, SNRIs, prazosin — address neurotransmitter balance but leave the inflammatory substrate largely untreated. This is a core reason why 40–60% of PTSD patients fail to achieve remission.
3.6 million treatment-resistant PTSD patients have already exhausted every approved option. Only 2 FDA-approved drugs exist for the primary indication — both over 20 years old — and neither addresses the neurobiological substrate. These same inflammatory markers (IL-6, TNF-α, IL-17, interferon α/β) are central to autoimmune biology — a convergence we think is worth measuring as an exploratory signal in the pilot, not a second indication.
Passos et al. (2015). "Inflammatory markers in post-traumatic stress disorder: a systematic review, meta-analysis, and meta-regression." JAMA Psychiatry, 72(2), 192–200. Meta-analysis of 20 studies, N>1,000.
Spravato (esketamine nasal spray) received FDA approval in 2019 for treatment-resistant depression — not PTSD. While its mechanism is highly relevant, its in-clinic model and $6,000–8,000/month price tag create a prohibitive access barrier. Meanwhile, unregulated compounded troches ($100–150/month, no oversight, dissociative doses) fill the vacuum with no FDA path, no insurance pathway, and no standardized safety monitoring.
The gap between Spravato and unregulated troches is where Project Lucid lives: FDA-regulated, low-dose, at-home, and designed from the ground up for PTSD.
These same PTSD patients carry 2× the rate of autoimmune disease (O’Donovan et al., 2015; N=666,269; confirmed by Mandagere et al. 2025 meta-analysis, N=1.98M, RR=1.291). The mechanism that rewires trauma also modulates the immune pathways targeted by Skyrizi, Cosentyx, and Humira — a mechanistic convergence worth investigating in the pilot biomarker panel.
The competitive landscape shifted materially in August 2024, when the FDA rejected MDMA-assisted therapy for PTSD — the most high-profile novel approach in years — citing data integrity concerns and functional unblinding limitations inherent to psychedelic trials. The rejection underscores investor demand for candidates with cleaner, placebo-controlled evidence packages. Ketamine’s RCT record in PTSD is precisely that.
The 50mg sublingual esketamine film (manufactured by LTS Lohmann) operates through two complementary mechanisms simultaneously — rapid neuroplasticity induction and direct anti-inflammatory action. Project Lucid’s clinical program is the first to test this film for PTSD with an integrated exploratory neuroimmune biomarker panel.
Durability comes from frequency — not dose. And the same mechanism that rewires trauma modulates IL-17, TNF-α, and interferon signaling — the targets of Skyrizi, Humira, and Cosentyx.
NMDA receptor antagonism triggers downstream BDNF release, promoting synaptogenesis in the prefrontal cortex and hippocampus within hours — not weeks.
Esketamine directly suppresses pro-inflammatory cytokines IL-6 and TNF-α — addressing the neuroinflammatory substrate that conventional PTSD treatments leave untreated.
Sublingual film achieves ~29% bioavailability with rapid Tmax (~19 min) — parent-drug Cmax comparable to Spravato 56–84mg intranasal — without requiring in-clinic administration after the first supervised dose.
| Dimension | Project Lucid | Spravato (J&J) | IV Ketamine Clinics | Compounded Troches |
|---|---|---|---|---|
| Delivery | Sublingual film | Nasal spray | Intravenous infusion | Sublingual troche (lozenge) |
| Active Ingredient | Esketamine (50mg) | Esketamine (56–84mg) | Racemic ketamine | Racemic ketamine (compounded) |
| Setting | At-home after first clinic dose | In-clinic only (2-hr monitoring) | In-clinic only (45–60 min infusion) | At-home, unsupervised |
| Dosing Frequency | 3×/week | 2×/week → 1×/week maintenance | Varies (1–2×/week) | Variable (prescriber-dependent) |
| PTSD Indication | Primary target | Not indicated (TRD only) | Off-label | Off-label, unregulated |
| Neuroimmune Mechanism | Core thesis: dual-pathway | Not positioned | Not positioned | Not positioned |
| Dose Level | Sub-dissociative | Can be dissociative | Often dissociative | Often dissociative |
| Cost Model | Designed for accessibility | ~$900/session (before insurance) | $400–800/infusion | $100–150/month (cash pay) |
| Reimbursement Target | Insurance-reimbursable target | Limited (specialty pharmacy) | Rarely covered | Not covered (no FDA path) |
The sublingual film is the therapeutic. The digital monitoring platform is what makes at-home administration safe, measurable, and scalable. This is the technology our patent protects.
All 12 doses administered under direct clinical supervision with 2-hour post-dose monitoring. Vitals, CADSS, and SpO₂ collected at every session. Establishes the baseline safety profile.
First doses in clinic, maintenance doses transition to at-home with real-time digital monitoring. The platform tracks vitals, mood, dissociation, and safety checkpoints — flagging alerts to the treating clinician before, during, and after each dose.
FDA-regulated at-home esketamine with continuous digital safety infrastructure. Remote vitals, real-time dissociation scoring, between-dose symptom tracking, telehealth check-ins, and automated safety escalation. Positioned as a psychiatric therapy with a reimbursement target comparable to Spravato.
Patent-pending: Digital Systems for Remote Administration and Monitoring of Sublingual Esketamine for PTSD (Provisional Serial Nos. 63/785,736; 63/799,047; 63/804,512). PCT international application filed April 2026.
Ketamine follows an inverted–U curve: too little is sub-therapeutic, too much is dissociative. Spravato’s fixed 56/84mg steps miss the optimum for many patients. Project Lucid is designed for dose individualization — 25mg tiles combine to deliver 25, 50, 75, 100, 125, or 150mg per session within a single label.
A differentiated, defensible label at Phase 3. Supported by Irfan-Husain et al. IV ketamine dose-response data.
Spravato’s REMS mandates in-clinic observation for every dose. Project Lucid’s platform captures HR, SpO₂, dissociation (CADSS), and symptom data remotely — designed to demonstrate non-inferiority to in-clinic observation and unlock an at-home label. Prior art for this class of monitoring (MindMed/definium SMS with wearable) has already cleared an FDA pre-submission.
Project Lucid is an IRB-ready Phase 1/2 open-label pilot — N=12 (up to 15 enrolled) — studying 50mg sublingual esketamine 3×/week for 4 weeks in adults with PTSD and a co-occurring inflammatory/autoimmune condition. CAPS-5 is the primary endpoint. Inflammatory biomarkers and disease activity are exploratory signals that may inform future research. Each milestone below represents an investor catalyst event.
Protocol LUCID-PTSD-2026-001 (Version 2.1) is IRB-ready. PTSD with an integrated exploratory neuroimmune biomarker arm. Includes digital monitoring feasibility component, pre-specified SAP with O’Brien-Fleming alpha-spending, and autoimmune flare management protocol. 66-page protocol with 4-member DSMB (including rheumatologist).
ActiveEnrollment of N=12 adults with confirmed PTSD (CAPS-5 ≥ 26) and co-occurring autoimmune disease (RA, SLE, IBD, psoriasis/PsA, MS, AS, or thyroid). Expanded biomarker panel (IL-6, TNF-α, IL-17A, IFN-α, IL-10, CRP, BDNF, ESR) + disease activity scores (DAS28-CRP, SLEDAI-2K, PASI, EDSS, etc.) + wearable device and app data collection begins. EQ-5D-5L quality of life baseline.
IA-1 (N=3 completers): Safety-only review — AE profile, cardiovascular trajectory, CADSS, autoimmune flares, digital monitoring compliance. IA-2 (N=6 completers): Safety + conditional efficacy — aggregate CAPS-5 signal, autoimmune disease activity trends, digital concordance from 72 sessions. O’Brien-Fleming boundary: p < 0.0054 for early efficacy signal. Non-binding futility if conditional power < 20%.
Complete N=12 dataset across all four domains. PTSD: CAPS-5 d ≥ 0.8 + ≥40% response → Phase 2 RCT. Exploratory neuroimmune signal: informs future mechanistic research; not a go/no-go for a separate program. Safety: 0 drug-related SAEs + mean CADSS < 10. Digital: HR/SpO₂ concordance + CADSS r ≥ 0.70 + detection sensitivity ≥ 90% → at-home monitoring validated. Tipping-point robustness confirmed.
505(b)(2) IND application filing for PTSD indication. Phase 2 RCT design (N=60–80) with integrated at-home digital monitoring arm. Out-licensing and Series A ($15–25M) discussions catalyzed by the PTSD pivotal readout. If the exploratory neuroimmune signal is confirmed, it informs future mechanistic research partnerships.
All dosing sessions include 2-hour post-dose digital monitoring with validated dissociation assessment (CADSS at 40 minutes) and vital sign tracking. Explicit discharge criteria gate home release. C-SSRS suicidality screening at every visit. DSMB review after the first 6 patients. Stopping rules for any serious adverse event. The safety protocol was designed to demonstrate clinical viability — not just regulatory compliance.
The case for Project Lucid is not speculative — it rests on a converging body of clinical, pharmacokinetic, and mechanistic evidence. Repeated IV ketamine 3×/week produces PTSD response rates of 67–77% with Cohen's d up to 1.9. The 50 mg SL OTF achieves parent-drug Cmax comparable to Spravato 56–84 mg. And at-home sublingual ketamine has a robust real-world safety record across 11,441 patients.
Protocol: 6 IV infusions (0.5 mg/kg), 3×/week × 2 weeks. Directly establishes the 3×/week schedule as evidence-based for PTSD.
View on PubMedAmong the largest effect sizes ever reported in psychiatric pharmacotherapy. Project Lucid's digital platform is designed to deliver this combination model at home.
View on PubMed CentralThe 50 mg SL OTF — the same LTS Lohmann platform underlying Project Lucid — was characterized in a Phase 1 PK trial by Dahan et al. (2022). The key finding: the OTF achieves parent-drug S-ketamine Cmax of ~96 ng/mL, comparable to Spravato 56–84 mg intranasal — not half a Spravato 28 mg, as the lower systemic AUC might suggest.
| Parameter | 50 mg SL OTF Project Lucid |
Spravato 28 mg IN | Spravato 56 mg IN | Spravato 84 mg IN |
|---|---|---|---|---|
| Bioavailability | ~29% | ~48% | ~48% | ~48% |
| Systemic S-ket delivered | ~14.5 mg | ~13.4 mg | ~26.9 mg | ~40.3 mg |
| S-ketamine Cmax (ng/mL) | ~96 | 43.8 | 72.5 | 101.0 |
| S-norketamine Cmax (ng/mL) | ~276 | 59.1 | 119.7 | 180.0 |
| Norketamine : Ketamine ratio | ~4.6× | ~1.4× | ~1.7× | ~1.8× |
| Tmax (min) | ~19 | 20–40 | 20–40 | 20–40 |
Source: Dahan et al. 2022 (OTF); J&J / FDA Clinical Pharmacology Review (Spravato). IN = intranasal. Spravato bioavailability includes nasal + GI components.
The SL route’s heavy hepatic first-pass metabolism generates a pharmacologically advantageous metabolite profile. S-norketamine Cmax (276 ng/mL) is 4.6× the parent drug — vs. 1.4–1.8× for Spravato intranasal. The OTF also generates meaningful S-hydroxynorketamine (S-HNK, Cmax ~101 ng/mL), essentially absent in intranasal delivery. Both metabolites carry independent antidepressant and synaptogenic activity without dissociative or abuse-related properties. The SL route is not a compromise — it is a feature.
This metabolite advantage now has transcriptomic confirmation: Wellington et al. (2025, OKTOP cohort) demonstrated that oral ketamine induces a two-phase immune response in PTSD patients — acute IL-6/IL-1β suppression followed by sustained immune reconstitution with an 8.8-fold increase in pathway activity. The modulated pathways (IL-17 z=3.36, interferon α/β z=4.0, cytokine storm z=4.26) are the same targets as Skyrizi (IL-23/IL-17), Cosentyx (IL-17A), Humira (TNFα), and Actemra (IL-6). This provides mechanistic support for the exploratory neuroimmune biomarkers Project Lucid is measuring in the pilot.
An honest appraisal of what is known, what is inferred, and what gap Project Lucid fills.
| Scientific Dimension | Evidence Level | Key Sources |
|---|---|---|
| PTSD unmet need | Strong | VA/DoD CPG 2023; PTSD market data |
| Ketamine efficacy in PTSD (3×/week IV) | Strong (RCT) | Feder 2021, Feder 2025 |
| 50 mg OTF pharmacokinetics | Strong (Phase 1) | Dahan et al. 2022 |
| Therapeutic dose adequacy of 50 mg OTF | Moderate-Strong | Cmax ~96 ng/mL comparable to Spravato 56–84 mg |
| S-HNK / S-norketamine metabolite activity | Moderate–Strong | Zanos 2016; Bottemanne 2025; Wellington 2025 (OKTOP transcriptomics: 8.8× pathway activation via oral route) |
| 3×/week schedule neuroplasticity rationale | Strong | ASL imaging; Singh et al.; Feder protocols |
| Fear reconsolidation mechanism | Moderate (Phase 2) | Morrison et al. 2023 |
| At-home SL ketamine safety (N=11,441) | Strong (prospective) | Wolfson et al. 2023; Mindbloom PTSD data |
| Long-term esketamine safety (129 sessions) | Moderate (N=20) | Bozan et al. 2026; SUSTAIN-3 |
| SL esketamine efficacy specifically in PTSD | Absent — gap we fill | N/A — rationale by extrapolation. This is what LUCID-PTSD-2026-001 directly addresses. |
Pivotal RCT establishing 3×/week ketamine as evidence-based for PTSD. 67% vs. 20% response rate; d=1.13; CAPS-5 reduction of 11.9 points vs. 2.4 for midazolam.
View on PubMedOpen-label trial combining 3×/week IV ketamine with WET. d=1.9 — among the largest effect sizes in psychiatric pharmacotherapy. 69% response at Week 12; 61.5% no longer meeting DSM-5 criteria at 6 months.
View on PMCPhase 1 PK trial of the LTS 50 mg S-ketamine OTF. Establishes ~29% bioavailability, Cmax ~96 ng/mL (comparable to Spravato 56–84 mg), and the 4.6× norketamine metabolite advantage.
View on PMCRandomized crossover study (N=27) showing ketamine after trauma memory reactivation significantly reduced amygdala reactivity to trauma cues at 30-day follow-up. Direct evidence that ketamine can rewrite traumatic memories during the reconsolidation window.
View on NatureLargest prospective safety dataset for sublingual ketamine. At average doses 7× the Project Lucid dose: adverse events 3–5%, serious adverse events 0.05%, intense dissociation requiring discontinuation 0.1%. No drug-related fatalities.
View on PMCMost comprehensive long-term esketamine safety data to date: 20 TRD patients, mean 129 intranasal sessions over 2.5 years. No serious adverse events. Side effects mild and transient at all sessions. 85% of patients improved after 129 sessions.
View on PMCMeta-analysis of 20 studies (N>1,000) demonstrating significantly elevated IL-6, IL-1β, and CRP in PTSD. Establishes the neuroinflammatory substrate that esketamine directly targets through cytokine suppression.
View on PubMedComprehensive review of NMDA receptor antagonism, downstream BDNF upregulation, and AMPA potentiation. Establishes that the therapeutic mechanism extends well beyond glutamate modulation and supports the rationale for repeated sub-dissociative dosing.
View on PubMedReal-world dataset of 1,247 patients receiving at-home sublingual ketamine. Significant improvement at 1, 2, and 3 months. Directly validates Project Lucid’s delivery route and monitoring model at scale.
View on PubMed6-week low-dose oral ketamine trial in 25 PTSD patients. Confirmed BDNF and VEGF-A changes — the first comprehensive biomarker evidence that oral ketamine drives neuroplasticity-mediated PTSD symptom reduction. Direct biological analog to Project Lucid’s sublingual delivery model.
Double-blind, active-controlled crossover RCT in 33 treatment-resistant PTSD patients. IM ketamine vs. fentanyl (psychoactive control). Ketamine at 1 mg/kg produced substantial, sustained PTSD severity reduction (IESR). Confirms efficacy even against an active psychoactive comparator — ruling out placebo or expectancy effects.
RNA transcriptomics in N=23 PTSD patients receiving 6-week oral ketamine. Identified 1,154 differentially expressed genes with an 8.8-fold enhancement in pathway activity from short-term to sustained timepoints. Demonstrated a two-phase immune response: acute pro-inflammatory cytokine suppression (IL-6, IL-1β, CXCL8) followed by sustained immune reconstitution and tissue repair. Key pathways: interferon α/β signalling, IL-17, cytokine storm modulation. The most granular molecular proof to date that oral ketamine directly addresses the neuroinflammatory substrate in PTSD — and the strongest validation of Project Lucid’s Aim 3 biomarker strategy.
View on PubMedThe same inflammatory substrate that perpetuates PTSD — chronically elevated IL-6, TNF-α, IL-17, and interferon signaling — is central to autoimmune disease. PTSD patients carry 2× the rate of autoimmune conditions (O’Donovan et al., 2015; N=666,269). Oral ketamine modulates these identical pathways, establishing why Project Lucid measures inflammatory biomarkers as an exploratory arm in the PTSD pilot.
N=666,269 veterans. Adjusted relative risk of 2.00 for any autoimmune disorder in PTSD vs. no psychiatric diagnosis; 1.51 vs. other psychiatric conditions. First large-scale demonstration that PTSD specifically — not psychiatric illness generally — drives autoimmune risk. Foundational epidemiological basis for measuring inflammatory biomarkers in the PTSD pilot.
View on PubMedSwedish population cohort, N=1.2 million. PTSD diagnosis associated with HR=1.46 for any autoimmune disease and HR=2.29 for ≥3 simultaneous autoimmune conditions. Incidence 9.1 vs. 6.0 per 1,000 person-years. Published in JAMA — the highest-impact confirmation of the PTSD-autoimmune comorbidity, and the rationale for measuring inflammatory biomarkers in PTSD trials.
View on PubMedFirst comprehensive meta-analysis of the PTSD-autoimmune association. N=1.98 million across multiple cohorts. Pooled RR=1.291 (95% CI: 1.179–1.412). Confirms the association is robust, consistent across study designs, and not driven by any single cohort or autoimmune subtype. The definitive quantitative synthesis of the PTSD-autoimmune comorbidity — grounding the exploratory biomarker panel.
View on PMCDemonstrated that ketamine directly suppresses Th17 cell differentiation via STAT3/IL-21 pathway inhibition. In an experimental autoimmune encephalomyelitis (EAE) model — the standard animal model for MS — ketamine reduced clinical disease scores from 2.83 to 0.25 (p=0.0025). The most direct mechanistic evidence that ketamine modulates the Th17/Treg axis — supporting the rationale for measuring IL-17 and related biomarkers as exploratory signals in the PTSD pilot.
View on PMCThe key transcriptomic evidence. RNA transcriptomics in N=23 PTSD patients on 6-week oral ketamine. Demonstrated modulation of IL-17 signaling (z=3.36), interferon α/β (z=4.0), cytokine storm (z=4.26), and neutrophil degranulation (z=6.0) — the identical pathways targeted by Skyrizi, Cosentyx, Humira, and Actemra. 8.8-fold enhancement in pathway activity from short-term to sustained timepoints. Provides the mechanistic rationale for why Project Lucid measures these inflammatory pathways as exploratory biomarkers in the PTSD pilot.
View on PubMedMillennium Cohort Study, N=120,572 active duty. HR=1.58 for composite autoimmune outcome in PTSD vs. non-PTSD. Critically, behavioral factors (smoking, BMI, alcohol) barely attenuated the effect — demonstrating the PTSD-autoimmune link is biologically mediated, not explained by lifestyle confounders. Strongest evidence for a direct inflammatory pathway.
View on PMCThe Wellington transcriptomic data demonstrates that oral ketamine modulates IL-17, interferon, and TNF-α pathways in PTSD patients. The Lee et al. EAE data demonstrates that ketamine directly suppresses Th17 cell differentiation. The O’Donovan, Song, and Mandagere epidemiological data confirms that PTSD and autoimmune disease share a measurable inflammatory substrate. These bodies of evidence are why Project Lucid collects inflammatory biomarkers and disease activity scores as exploratory endpoints in the PTSD pilot — not as a go/no-go for a separate program, but as a mechanistic hypothesis worth measuring.
Dallas-based psychiatrist and PTSD specialist who developed Project Lucid directly from clinical ketamine experience. Sponsor-Investigator of LUCID-PTSD-2026-001 — an IRB-ready Phase 1/2 open-label pilot of 50mg sublingual esketamine for PTSD with co-occurring autoimmune disease.
The clinical premise of Project Lucid sits at the intersection of three bodies of evidence that have not previously been connected: Feder et al.’s RCT-validated 3×/week IV ketamine protocol, Dahan et al.’s Phase 1 PK characterization of the 50mg SL OTF, and Wolfson et al.’s at-home safety dataset of N=11,441. The synthesis is Dr. Idell’s.
Protocol LUCID-PTSD-2026-001 is patent-pending (administration protocol and digital monitoring system), IRB-ready, and targeting Q4 2026 enrollment. Dr. Idell is the Sponsor-Investigator.
Dr. Mukesh Kumar, PhD, RAC
CEO & Founder, FDAMap — Washington, DC. 20+ years in FDA regulatory affairs. 150+ clinical trials across 34 countries. Confirmed 505(b)(2) pathway viability for Project Lucid.
Dr. Steven Idell, MD, PhD
Pulmonary & Critical Care Physician. Temple Chair in Pulmonary Fibrosis. 40 years of continuous NIH funding. Founder of Lung Therapeutics (acquired → Rein Therapeutics). Deep translational drug development expertise.
EMMES Corporation
Full-service CRO engaged for Phase 1/2 pilot study design. Specializes in Phase I–IV trials, biostatistics, pharmacovigilance, and FDA regulatory affairs. AI-enabled trial management.
The Other Side
Jon Nelson and Mark Slater — patient-led organization integrating lived experience into Project Lucid from protocol design forward.
A $3.5B PTSD market with no approved biologic, no novel mechanism approved in 25 years, and a 50% first-line treatment failure rate. Project Lucid is designed to fill that gap with a regulatory pathway confirmed, human PK data in hand, and an integrated exploratory neuroimmune biomarker panel that may generate mechanistic insights for future research.
PTSD patients carry 2× the rate of autoimmune disease (O’Donovan et al., 2015; N=666,269). Wellington et al. (2025) demonstrated that oral ketamine modulates the identical inflammatory pathways as leading autoimmune biologics — IL-17 signaling, interferon α/β, and cytokine storm pathways. Project Lucid’s Phase 1/2 enrolls patients with co-occurring PTSD and an inflammatory/autoimmune condition, using CAPS-5 as the primary endpoint and collecting inflammatory biomarkers as exploratory signals.
Primary CAPS-5 endpoint. 505(b)(2) IND pathway confirmed. Phase 2 RCT → NDA. Positioned alongside Spravato at ~$64K/year reimbursement.
IL-6, TNF-α, IL-17A, IFN-α, CRP, BDNF, and disease activity scores collected as exploratory endpoints. If confirmed, informs future mechanistic research. Not a go/no-go for a separate program.
The Phase 1/2 data is the primary catalyst. A confirmed PTSD efficacy signal drives the IND and Phase 2 RCT. A confirmed exploratory neuroimmune signal informs future mechanistic research partnerships.
| Project Lucid | Spravato® (J&J) | IV Ketamine Clinics | Compounded Troches | Autoimmune Biologics | |
|---|---|---|---|---|---|
| PTSD Indication | Phase 1/2 active | Not indicated | Off-label | Off-label, unregulated | Not applicable |
| Neuroimmune Biomarkers | Exploratory endpoints in PTSD pilot | Not collected | Not collected | Not collected | Indication-specific only |
| Integrated Biomarker Panel | Yes — exploratory neuroimmune arm | No | No | No | No (psychiatric comorbidity not addressed) |
| Route | Sublingual film (at-home target) | Intranasal (in-clinic REMS) | IV infusion (in-clinic) | Oral (unregulated) | IV infusion / SC injection |
| Digital Monitoring | Wearable + app (patent-pending) | None (clinician only) | None | None | None |
| Inflammatory Biomarkers | IL-6, TNF-α, IL-17A, IFN-α, IL-10, CRP, BDNF, ESR | Not collected | Not collected | Not collected | Indication-specific only |
| Reimbursement Target | ~$64K/yr (PTSD psychiatric therapy) | ~$64K/yr (TRD only) | $5–10K/yr (cash pay) | $1–2K/yr (cash pay) | $64–250K/yr |
| FDA Pathway | 505(b)(2) confirmed | Approved (TRD) | None (off-label) | None | BLA (each drug) |
| Pre-Specified Go/No-Go | 4 domains + tipping-point | N/A (approved) | N/A | N/A | Standard Phase 3 |
| At-Home Scalability | Designed for it — digital REMS path | Blocked by REMS † | Impossible (IV access) | Unregulated — no FDA path | SC self-inject only (no monitoring) |
| † Spravato’s REMS (Risk Evaluation and Mitigation Strategy) mandates in-clinic administration with 2-hour post-dose observation by a healthcare provider for every dose — a structural barrier to at-home scalability that cannot be removed without a new NDA supplement. The FDA rejected MDMA-assisted therapy for PTSD in August 2024 (Lykos Therapeutics), citing data integrity concerns and functional unblinding — eliminating the only other novel PTSD candidate with a home-adjacent delivery model. Project Lucid’s sublingual film, combined with the digital monitoring concordance dataset from Phase 1/2, is designed to be the first esketamine product to demonstrate non-inferiority of remote monitoring vs. in-clinic observation — the regulatory prerequisite for at-home FDA authorization. | |||||
No other clinical program is testing an NMDA antagonist for PTSD with an integrated exploratory neuroimmune biomarker panel. Project Lucid is the only trial designed to measure this inflammatory signal in a PTSD patient population.
Before a single patient is enrolled, the protocol locks in a tipping-point analysis that stress-tests the primary result. Missing data is imputed at progressively worse outcomes — from last-observed value through return-to-baseline and beyond — to answer: how wrong would we need to be for the finding to disappear?
These thresholds are locked in the protocol (Section 7.10.7) before enrollment begins — not chosen after seeing the data. Combined with an O’Brien-Fleming alpha-spending function and a pre-registered SAP, this is the analytical rigor investors and the FDA expect for an IND-enabling dataset.
Whether you're evaluating an investment or exploring a clinical collaboration, we welcome direct conversations.
Seed-stage funding opportunity. Supporting Phase 1/2 pilot completion, biomarker data collection, and IND preparation. Reach out to receive the full investor deck, protocol summary, and financial projections.
Academic medical center partnerships, site collaboration, and key opinion leader engagement. Trauma psychiatrists, psychopharmacologists, and drug delivery researchers are welcome to reach out about the science and study design.
